Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

At ESMO TAT meeting, translating translation inhibition

March 3, 2021

Poziotinib twice daily effective in patients with EGFR/HER2 exon 20-mutant NSCLC

March 3, 2021

Phase I data reported for CC-90010 in patients with solid tumors

March 3, 2021

Applied Pharmaceutical Science identifies new RET inhibitors

March 3, 2021

First-in-human data presented for SCC-244 in NSCLC

March 3, 2021

AbbVie initiates first-in-human study of ABBV-637 as monotherapy or in combination

March 3, 2021

Carna receives CTA clearance for phase I study of BTK inhibitor AS-1763

March 2, 2021

FDA issues complete response letter for oral paclitaxel plus encequidar in metastatic breast cancer

March 2, 2021

Myoferlin inhibitor YQ-456 shows efficacy in PDX model of colorectal cancer

March 2, 2021

Alofanib shows safety and antitumor efficacy in patients with advanced gastric cancer

March 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...